Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants

Irving Sivin; Pekka Lähteenmäki; Sirpa Ranta; Philip Darney; Cindy Klaisle; Livia Wan; Daniel R. Mishell; Maria Lacarra; Osborn A.C. Viegas; Prapas Bilhareus; Suporn Koetsawang; Manee Piya-Anant; Soledad Diaz; Margarita Pavez; Francisco Alvarez; Vivian Brache; Katherine LaGuardia; Harold Nash; Janet Stern

doi:10.1016/S0010-7824(96)00276-4

Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants

Irving Sivin, Pekka Lähteenmäki, Sirpa Ranta, Philip Darney, Cindy Klaisle, Livia Wan, Daniel R. Mishell, Maria Lacarra, Osborn A.C. Viegas, Prapas Bilhareus, Suporn Koetsawang, Manee Piya-Anant, Soledad Diaz, Margarita Pavez, Francisco Alvarez, Vivian Brache, Katherine LaGuardia, Harold Nash, Janet Stern

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Abstract

In a three-year randomized trial that included 398 women, blood samples were collected for the purpose of assaying levonorgestrel concentrations in women using a new two-rod contraceptive implant system or an earlier implant formulation, Norplant®-2 implants. Sample collection was at 1, 3, 6, 9, and 12 months after placement and semiannually thereafter through three years. Resulting assays and analyses showed that levonorgestrel concentrations of each implant formulation decreased significantly with time after placement, with increasing body weight, and with ponderal index. In the third year, several measures indicated that concentrations of the contraceptive drug were higher in women using the LNG ROD implants than in users of the original formulation. No pregnancies occurred among women in either group in the three years. This study provides evidence that the minimum levonorgestrel concentration needed to protect against pregnancy is below 200 pg/ml, and possibly is below 175 pg/ml.

Original language	English
Pages (from-to)	81-85
Number of pages	5
Journal	Contraception
Volume	55
Issue number	2
DOIs	https://doi.org/10.1016/S0010-7824(96)00276-4
State	Published - Feb 1997
Externally published	Yes

Keywords

contraception
implants
levonorgestrel concentrations
rod implants

Access to Document

10.1016/S0010-7824(96)00276-4

Cite this

Sivin, I., Lähteenmäki, P., Ranta, S., Darney, P., Klaisle, C., Wan, L., Mishell, D. R., Lacarra, M., Viegas, O. A. C., Bilhareus, P., Koetsawang, S., Piya-Anant, M., Diaz, S., Pavez, M., Alvarez, F., Brache, V., LaGuardia, K., Nash, H., & Stern, J. (1997). Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception, 55(2), 81-85. https://doi.org/10.1016/S0010-7824(96)00276-4

@article{3a9cf5e7fcb749108582c8ce25ebe730,

title = "Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants",

abstract = "In a three-year randomized trial that included 398 women, blood samples were collected for the purpose of assaying levonorgestrel concentrations in women using a new two-rod contraceptive implant system or an earlier implant formulation, Norplant{\textregistered}-2 implants. Sample collection was at 1, 3, 6, 9, and 12 months after placement and semiannually thereafter through three years. Resulting assays and analyses showed that levonorgestrel concentrations of each implant formulation decreased significantly with time after placement, with increasing body weight, and with ponderal index. In the third year, several measures indicated that concentrations of the contraceptive drug were higher in women using the LNG ROD implants than in users of the original formulation. No pregnancies occurred among women in either group in the three years. This study provides evidence that the minimum levonorgestrel concentration needed to protect against pregnancy is below 200 pg/ml, and possibly is below 175 pg/ml.",

keywords = "contraception, implants, levonorgestrel concentrations, rod implants",

author = "Irving Sivin and Pekka L{\"a}hteenm{\"a}ki and Sirpa Ranta and Philip Darney and Cindy Klaisle and Livia Wan and Mishell, {Daniel R.} and Maria Lacarra and Viegas, {Osborn A.C.} and Prapas Bilhareus and Suporn Koetsawang and Manee Piya-Anant and Soledad Diaz and Margarita Pavez and Francisco Alvarez and Vivian Brache and Katherine LaGuardia and Harold Nash and Janet Stern",

note = "Funding Information: This study was financed by cooperative agreements DPE 2050-A-00-8059-00 and CCP-3050-A-00-4013-00 from the US Agency for International Development and grants from the United Nations Population Fund (UNFPA), The George J. Hecht Family Trust, The Rockefeller Foundation, the Andrew W. Mellon Foun- dation, and Wyeth-Ayerst Research and is part of the Contraceptive Development program at the Population Council{\textquoteright}s Center for Biomedical Research.",

year = "1997",

month = feb,

doi = "10.1016/S0010-7824(96)00276-4",

language = "English",

volume = "55",

pages = "81--85",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier Inc.",

number = "2",

}

Sivin, I, Lähteenmäki, P, Ranta, S, Darney, P, Klaisle, C, Wan, L, Mishell, DR, Lacarra, M, Viegas, OAC, Bilhareus, P, Koetsawang, S, Piya-Anant, M, Diaz, S, Pavez, M, Alvarez, F, Brache, V, LaGuardia, K, Nash, H & Stern, J 1997, 'Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants', Contraception, vol. 55, no. 2, pp. 81-85. https://doi.org/10.1016/S0010-7824(96)00276-4

TY - JOUR

T1 - Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants

AU - Sivin, Irving

AU - Lähteenmäki, Pekka

AU - Ranta, Sirpa

AU - Darney, Philip

AU - Klaisle, Cindy

AU - Wan, Livia

AU - Mishell, Daniel R.

AU - Lacarra, Maria

AU - Viegas, Osborn A.C.

AU - Bilhareus, Prapas

AU - Koetsawang, Suporn

AU - Piya-Anant, Manee

AU - Diaz, Soledad

AU - Pavez, Margarita

AU - Alvarez, Francisco

AU - Brache, Vivian

AU - LaGuardia, Katherine

AU - Nash, Harold

AU - Stern, Janet

N1 - Funding Information: This study was financed by cooperative agreements DPE 2050-A-00-8059-00 and CCP-3050-A-00-4013-00 from the US Agency for International Development and grants from the United Nations Population Fund (UNFPA), The George J. Hecht Family Trust, The Rockefeller Foundation, the Andrew W. Mellon Foun- dation, and Wyeth-Ayerst Research and is part of the Contraceptive Development program at the Population Council’s Center for Biomedical Research.

PY - 1997/2

Y1 - 1997/2

N2 - In a three-year randomized trial that included 398 women, blood samples were collected for the purpose of assaying levonorgestrel concentrations in women using a new two-rod contraceptive implant system or an earlier implant formulation, Norplant®-2 implants. Sample collection was at 1, 3, 6, 9, and 12 months after placement and semiannually thereafter through three years. Resulting assays and analyses showed that levonorgestrel concentrations of each implant formulation decreased significantly with time after placement, with increasing body weight, and with ponderal index. In the third year, several measures indicated that concentrations of the contraceptive drug were higher in women using the LNG ROD implants than in users of the original formulation. No pregnancies occurred among women in either group in the three years. This study provides evidence that the minimum levonorgestrel concentration needed to protect against pregnancy is below 200 pg/ml, and possibly is below 175 pg/ml.

AB - In a three-year randomized trial that included 398 women, blood samples were collected for the purpose of assaying levonorgestrel concentrations in women using a new two-rod contraceptive implant system or an earlier implant formulation, Norplant®-2 implants. Sample collection was at 1, 3, 6, 9, and 12 months after placement and semiannually thereafter through three years. Resulting assays and analyses showed that levonorgestrel concentrations of each implant formulation decreased significantly with time after placement, with increasing body weight, and with ponderal index. In the third year, several measures indicated that concentrations of the contraceptive drug were higher in women using the LNG ROD implants than in users of the original formulation. No pregnancies occurred among women in either group in the three years. This study provides evidence that the minimum levonorgestrel concentration needed to protect against pregnancy is below 200 pg/ml, and possibly is below 175 pg/ml.

KW - contraception

KW - implants

KW - levonorgestrel concentrations

KW - rod implants

UR - http://www.scopus.com/inward/record.url?scp=0343683454&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(96)00276-4

DO - 10.1016/S0010-7824(96)00276-4

M3 - Article

C2 - 9071516

AN - SCOPUS:0343683454

SN - 0010-7824

VL - 55

SP - 81

EP - 85

JO - Contraception

JF - Contraception

IS - 2

ER -

Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants

Abstract

Keywords

Access to Document

Fingerprint

Cite this